Jardiance reduces risk of progressive kidney disease in type 2 diabetes
New data showed Jardiance (empagliflozin) reduced the risk for new-onset or worsening kidney disease by 39% versus placebo when added to standard of care in adults with type 2 diabetes with established cardiovascular disease.
Click on this link for more information.
